Solventum (NYSE: SOLV) reported third-quarter sales of $1.9 billion, down 7.0% from a year earlier. Organic sales fell 2.8%, which the company blamed on customers' advance orders in the second quarter ahead of an ERP system cutover. Adjusted earnings per share were $1.45, down 3.6%. The company posted a GAAP loss of $0.07 per share. Operating cash flow was $177 million and free cash flow $97 million, helped by an IEEPA tariff refund. Solventum raised its full-year adjusted earnings per share guidance to $7.20 to $7.30, from $7.10 to $7.20. It expects organic sales growth toward the high end of 2.5% to 3.0%. The company has exited about 90% of its 3M transition service agreements, and its ERP cutovers are complete.

Solventum has received US Food and Drug Administration (FDA) 510(k) clearance to use Restrata Synthetic Electrospun Fiber Matrix together with its V.A.C. Therapy, the company announced on October 19, 2026. The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully synthetic, resorbable matrix that supports soft tissue repair, while V.A.C. Therapy applies negative pressure to promote wound healing. Solventum says the matrix resists enzymatic degradation and matches the dressing's wear time of up to seven days. Many collagen-based dressings degrade too early for such use. The pairing may mean fewer dressing changes and a more predictable workflow for care teams. "We're giving clinicians an effective way to streamline care and support better patient outcomes," said Kelley Moffett, president of Advanced Wound Care at Solventum.

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.